Pinned Tweet
SpliceBio takes over Times Square! 🗽
Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower.
Huge thanks to our team & investors powering the next wave of genetic medicines! 💡
Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower.
Huge thanks to our team & investors powering the next wave of genetic medicines! 💡
1
1
8
1,470
At #ESGCT2026, we enjoyed connecting with the community and sharing our latest #neurology research. Our first poster in this area highlighted our protein splicing platform in the CNS and its potential to support the development of genetic medicines for neurological disorders.
0
1
3
141
Last week, our CEO and CFO attended the Galien Patient Summit, connecting with patient advocates and leaders across the healthcare community who share one goal: better outcomes for patients. Thank you @GalienFdn for an inspiring night.
0
0
1
51
Tomorrow, our CEO Miquel Vila-Perelló will join the @bcndeeptech summit for a fireside chat exploring what it takes to build and scale a genetic medicines company like SpliceBio. We look forward to meeting with fellow innovators and leaders across the deep tech ecosystem!
0
0
0
30
Next week, join our team at #ESGCT2026. We'll be presenting a poster highlighting SpliceBio’s protein splicing platform in the central nervous system (CNS), including translational validation in non-human primates. We look forward to connecting!
0
0
1
47
Our Clinical Project Manager Lauren Hauser (pictured in pink) recently represented SpliceBio at an event hosted by the @CarrollCenter. We value opportunities to connect with organizations like the Carroll Center that share our commitment to supporting the vision loss community.
0
0
3
61
This #WorldSightDay, we’re raising awareness of Stargardt disease and the impact progressive central vision loss can have on everyday activities like reading a book. At SpliceBio, we’re advancing SB-007, our investigational gene therapy for #Stargardt disease.
0
1
2
85
Join our CBO Gerard Caelles at #Sachs_BEF in Basel this week. He will present our work in #CNS and join the Neuroscience Innovation Panel with other industry leaders.
0
0
1
61
Our CEO Miquel Vila-Perello is heading to Phoenix for @alliancerm 2026 Cell & Gene Meeting on the Mesa.
We look forward to connecting with colleagues across the cell and gene therapy community on Monday and throughout the week. We’ll meet you at #CGMesa26!
We look forward to connecting with colleagues across the cell and gene therapy community on Monday and throughout the week. We’ll meet you at #CGMesa26!
0
0
1
58
We’re honored to be nominated for the 2026 Prix Galien Patient First Award in Honor of Michael J. Fox. This recognition reflects our work alongside the #StargardtDisease community to deepen our understanding of the disease and advance new treatment options. Thank you @GalienFdn.
0
1
2
75
At #ISER2026, our Head of Ophthalmology, Julián Esteve will present on how our protein splicing platform is overcoming AAV cargo limits to unlock delivery of large genes. He'll also share how the technology is being applied in SB-007, our lead program for #Stargardt disease.
0
0
1
280
Ens fa molta il·lusió haver donat suport al #BBQ2026 a patrocinadors Silver: la gran trobada d’estiu de la comunitat biotecnològica, healthtech i de ciències de la vida de Catalunya. Gràcies a @CataloniaHealth per una altra fantàstica edició. Ens veiem l'any vinent!
1
0
0
66
Grateful to have supported this year's #BBQ2026 as a Silver Sponsor: the flagship summer gathering for Catalonia's biotech, healthtech & life sciences community. Thanks to @CataloniaHealth for another great edition. See you next year!
0
0
0
20
Today is Rare Chromosome and Gene Disorder Awareness Day - a time to recognize the individuals and families affected by rare genetic conditions, including inherited retinal diseases such as #Stargardt disease. We honor their resilience and the importance of continued innovation.
0
1
1
78
Our CEO Miquel Vila-Perello joined RARECast by @GlobalGenes to talk about why many rare diseases have long been out of reach for gene therapy and how SpliceBio is working to change that.
1
0
1
60
This Monday, we're in Leicester for @UKEyeGenetics
Group (UK-EGG) 2026! Our CMO will present on conducting clinical trials, navigating the regulatory process and the importance of communication - fundamental elements to our mission of advancing #geneticmedicines.
Group (UK-EGG) 2026! Our CMO will present on conducting clinical trials, navigating the regulatory process and the importance of communication - fundamental elements to our mission of advancing #geneticmedicines.
0
0
1
45
Last week, our team came together for a retreat filled with reflection, connection, and plenty of laughs! Experiences like these reinforce something we believe deeply: investing in our people is essential to building a strong culture and advancing our mission.
0
0
1
476
#Stargardt disease is caused by mutations in ABCA4 - a gene too large for traditional gene therapy. We're advancing protein splicing to enable large-gene delivery and address the root cause of a disease with no approved treatments.
1
0
0
205
Great time at #ARVO2026 & #ASGCT2026! We were proud to share progress on our clinical program SB-007 for #Stargardt disease and engage in conversations with the broader #genetherapy community. Thank you to everyone who connected. We’re energized by the momentum!
0
0
2
173
#Stargardt disease has no approved treatments. This #HealthyVisionMonth, we’re raising awareness of inherited retinal diseases. At SpliceBio, we’re working to advance genetic medicines using protein splicing to address diseases caused by mutations in large genes.
0
0
0
123